Improving reputation and high return-on-investment fueling demand for Rutgers innovative MBA program
Looking for the skills necessary to succeed in the 21st Century economy? Rutgers Business School’s MBA program has developed an innovative curriculum with valuable hands-on experience to ensure graduates reach their career goals. More ›
Traditional Full-time MBA program still accepting applications for Fall 2013
This is the perfect time to earn an MBA and Rutgers Business School is extending application deadlines to meet the growing demand for business education. More ›

In a new 544-page book, Rutgers Business School Professor Jerome Williams and his co-editors, Keryn Pasch and Chiquita Collins, explore the powerful marketing tactics that influence the diets of children and teenagers, the policy questions raised by pervasive advertising and the possible strategies for addressing childhood obesity, an issue that is as complex as it is troubling. Rutgers Business School hosted an event on May 7 to discuss the book, ponder the implications of regulating marketing and to highlight the efforts currently underway in Newark to help children eat better and be more active. More ›

Extroverts versus Neurotics: New research shows neurotics deserve equal consideration as leaders
Neha Parikh Shah, an assistant professor who teaches organizational behavior at Rutgers Business School, co-authored a paper that is receiving lots of interest among those who care about the qualities of good managers, teams and business leaders. The paper is entitled, "The Downfall of Extroverts and the Rise of Neurotics: The Dynamic Process of Status Allocation in Task Groups.” It was published last month in the Academy of Management Journal. More ›

Lerner Center's annual symposium addresses bio-pharmaceutical industry's key challenges and trends
The healthcare symposium, which the Lerner Center has hosted for nearly a decade, attracted more than 100 people on April 30, including MBA students, Rutgers Business School administrators and employees from drug giants, Celgene, Merck, Johnson & Johnson as well as Ohm Laboratories, the generic drug maker. Mahmud Hassan, a finance professor and director of the Lerner Center, said the symposium is intended to be a setting for “a meaningful dialogue among the bio-pharmaceutical leaders, policy makers and the researchers on issues relevant to the growth of the bio-pharmaceutical industry.” More ›


